Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Biogen building
Biogen hopes to move from Phase I to Phase III with SMA candidate • Source: Shutterstock

Biogen is looking to improve the standard of care in spinal muscular atrophy with an aggressive development plan for Spinraza (nusinersen) follow-on salanersen (BIIB115), presenting Phase I data on June 25 at the SMA Research and Clinical Care meeting and outlining its goal to proceed directly from Phase I to a registrational Phase III program.

Key Takeaways
  • Biogen’s Phase I data for Spinraza follow-on salanersen shows ability to restore functioning SMN protein and reduce neurofilament levels, which may provide a disease-modifying effect.

Like Spinraza, salanersen is also an antisense oligonucleotide (ASO) therapy licensed from Ionis that acts to normalize production of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from R&D